Concurrent chemoradiotherapy with weekly versus three-weekly cisplatin in locally advanced head and neck squamous cell carcinoma

  • Protocol
  • Intervention

Authors

  • Thiagarajan Shivakumar,

    Corresponding author
    1. Advanced Centre for Treatment, Research & Education in Cancer (ACTREC), Tata Memorial Centre, Surgical Oncology (Head & Neck Services), Navi Mumbai, India
    • Thiagarajan Shivakumar, Surgical Oncology (Head & Neck Services), Advanced Centre for Treatment, Research & Education in Cancer (ACTREC), Tata Memorial Centre, Navi Mumbai, 410210, India. drshiva78in@gmail.com.

    Search for more papers by this author
  • Sudhir Nair,

    1. Advanced Centre for Treatment Research & Education in Cancer (ACTREC), Tata Memorial Centre, Surgical Oncology, Navi Mumbai, India
    Search for more papers by this author
  • Tejpal Gupta,

    1. Advanced Centre for Treatment Research & Education in Cancer (ACTREC), Tata Memorial Centre, Radiation Oncology, Navi Mumbai, India
    Search for more papers by this author
  • Sadhana Kannan

    1. Advanced Centre for Treatment Research & Education in Cancer (ACTREC), Tata Memorial Centre, Clinical Research Secretariat/Epidemiology & Clinical Trial Unit, Navi Mumbai, India
    Search for more papers by this author

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

Primary objective

To assess the efficacy of a weekly cisplatin regimen compared to a three-weekly regimen, given with curative intent to treat locally advanced HNSCC, in terms of overall survival (at five years).

Secondary objective

To assess the distant metastasis-free survival (at two years), disease-free survival (at two years) and the toxicity profile of the two regimens.